Sabby Volatility Fund Takes 9.99% Stake in iBio (IBIO)
Ticker: IBIO · Form: SC 13G · Filed: 2024-01-04T00:00:00.000Z
Sentiment: bullish
Topics: institutional-ownership, stake-acquisition, biotech, 13G-filing
TL;DR
**Sabby Volatility Fund just bought 9.99% of iBio (IBIO), signaling a big institutional bet.**
AI Summary
Sabby Volatility Warrant Master Fund, Ltd., an investment fund based in the Cayman Islands, has reported a significant stake in iBio, Inc. (IBIO). As of December 31, 2023, Sabby Volatility Warrant Master Fund, Ltd. beneficially owns 200,303 shares of iBio's Common Stock, representing 9.99% of the company's outstanding shares. This matters to investors because a large institutional investor taking a near-10% stake can signal confidence in the company's future, potentially attracting more investor interest and influencing stock price.
Why It Matters
This filing reveals a major institutional investor, Sabby Volatility Warrant Master Fund, Ltd., has acquired a substantial stake in iBio, Inc., which could be seen as a vote of confidence and potentially impact the stock's perception.
Risk Assessment
Risk Level: medium — While a large institutional investment can be positive, iBio is a pharmaceutical company, inherently carrying higher risks related to drug development and market acceptance.
Analyst Insight
A smart investor would monitor iBio's stock performance and news closely, considering this significant institutional stake as a potential positive catalyst, but also research Sabby Volatility Warrant Master Fund, Ltd.'s investment strategy to understand their typical holding periods and objectives.
Key Numbers
- 200,303 — Shares Beneficially Owned (The total number of iBio Common Stock shares Sabby Volatility Warrant Master Fund, Ltd. has shared voting and dispositive power over.)
- 9.99% — Ownership Percentage (The percentage of iBio's Common Stock owned by Sabby Volatility Warrant Master Fund, Ltd., calculated from the 200,303 shares.)
- December 31, 2023 — Event Date (The specific date that triggered the requirement for Sabby Volatility Warrant Master Fund, Ltd. to file this Schedule 13G.)
Key Players & Entities
- Sabby Volatility Warrant Master Fund, Ltd. (company) — reporting person, beneficial owner of iBio shares
- iBio, Inc. (company) — subject company, issuer of the securities
- Cayman Islands (person) — place of organization for Sabby Volatility Warrant Master Fund, Ltd.
- 200,303 (dollar_amount) — number of shares beneficially owned
- 9.99% (dollar_amount) — percentage of iBio's class of securities owned
- December 31, 2023 (person) — date of event requiring the filing
Forward-Looking Statements
- iBio's stock price may see increased volatility or upward movement due to institutional interest. (iBio, Inc.) — medium confidence, target: Q1 2024
- Other institutional investors might initiate or increase their positions in iBio, following Sabby's lead. (iBio, Inc.) — low confidence, target: Q2 2024
FAQ
Who is the reporting person in this SC 13G filing?
The reporting person is Sabby Volatility Warrant Master Fund, Ltd., as stated in Item 1 of the filing.
What is the total number of shares of iBio, Inc. Common Stock beneficially owned by the reporting person?
Sabby Volatility Warrant Master Fund, Ltd. beneficially owns 200,303 shares of iBio, Inc. Common Stock, as detailed in Item 9 of the filing.
What percentage of iBio, Inc.'s outstanding Common Stock does Sabby Volatility Warrant Master Fund, Ltd. own?
The filing indicates that Sabby Volatility Warrant Master Fund, Ltd. owns 9.99% of iBio, Inc.'s Common Stock, as per Item 13.
On what date did the event occur that required this SC 13G filing?
The event that required this filing occurred on December 31, 2023, as specified on the cover page of the Schedule 13G.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(c), as indicated by the checked box on the cover page.
From the Filing
EDGAR Filing Documents for 0001535610-24-000029 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home Company Search Current Page Form SC 13G - Statement of Beneficial Ownership by Certain Investors: SEC Accession No. 0001535610-24-000029 Filing Date 2024-01-04 Accepted 2024-01-04 08:00:38 Documents 1 Document Format Files Seq Description Document Type Size 1 IBIO 13G 1.04.24 ibio0124.txt SC 13G 11589 Complete submission text file 0001535610-24-000029.txt 13308 Mailing Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 Business Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 302 355-0650 iBio, Inc. (Subject) CIK : 0001420720 (see all company filings) EIN. : 262797813 | State of Incorp.: DE | Fiscal Year End: 0630 Type: SC 13G | Act: 34 | File No.: 005-84151 | Film No.: 24509790 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences) Mailing Address 115 HIDDEN HILLS DR SPICEWOOD TX 78669 Business Address 115 HIDDEN HILLS DR SPICEWOOD TX 78669 646-307-4527 SABBY MANAGEMENT, LLC (Filed by) CIK : 0001535610 (see all company filings) EIN. : 000000000 | State of Incorp.: DE | Fiscal Year End: 1231 Type: SC 13G